Published in Leukemia on February 22, 2007
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
Multiplexed nanoflares: mRNA detection in live cells. Anal Chem (2012) 1.15
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia (2010) 1.04
Impact of XIAP protein levels on the survival of myeloma cells. Haematologica (2008) 0.96
Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica (2012) 0.91
Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol (2009) 0.90
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol (2012) 0.88
Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol (2012) 0.88
Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis (2014) 0.86
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget (2014) 0.84
Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS One (2009) 0.84
Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells. Clin Lymphoma Myeloma Leuk (2015) 0.83
FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia (2015) 0.80
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol (2015) 0.79
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol (2014) 0.79
Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy (2013) 0.76
NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. BMC Cancer (2012) 0.76
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma. J Immunother Cancer (2015) 0.75
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLoS One (2017) 0.75
The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 15.12
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med (1996) 10.69
Hard-X-ray dark-field imaging using a grating interferometer. Nat Mater (2008) 5.19
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Synaptic vesicle endocytosis impaired by disruption of dynamin-SH3 domain interactions. Science (1997) 3.59
A presynaptic inositol-5-phosphatase. Nature (1996) 3.54
Hard x-ray phase tomography with low-brilliance sources. Phys Rev Lett (2007) 3.27
Hard-x-ray lensless imaging of extended objects. Phys Rev Lett (2007) 3.11
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Viridans streptococcal bacteraemia in patients with neutropenia. Lancet (1995) 2.46
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Actin-based movement of Listeria monocytogenes: actin assembly results from the local maintenance of uncapped filament barbed ends at the bacterium surface. J Cell Biol (1995) 2.27
ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie (2001) 2.23
Solitary myeloma: clinical and prognostic features of a review of 114 cases. Cancer (1981) 2.23
The SH3 domain of amphiphysin binds the proline-rich domain of dynamin at a single site that defines a new SH3 binding consensus sequence. J Biol Chem (1997) 2.16
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood (1994) 2.10
High-resolution brain tumor visualization using three-dimensional x-ray phase contrast tomography. Phys Med Biol (2007) 2.09
Expression of individual Ia specificities on T and B cells. I. Studies with mitogen-induced blast cells. J Exp Med (1976) 2.08
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia (2003) 2.07
Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of ranvier in brain and around T tubules in skeletal muscle. J Cell Biol (1997) 2.04
Interleukin-6 in human multiple myeloma. Blood (1995) 1.95
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood (2001) 1.93
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat (2001) 1.80
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76
Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood (1990) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
A two-directional approach for grating based differential phase contrast imaging using hard x-rays. Opt Express (2007) 1.72
Quantitative x-ray dark-field computed tomography. Phys Med Biol (2010) 1.72
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 1.67
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood (1999) 1.65
IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. Eur J Immunol (1999) 1.64
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood (2001) 1.62
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
No detectable malignant B cells in the peripheral blood of patients with multiple myeloma. Br J Haematol (1989) 1.60
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia (2010) 1.59
P53 deletion is not a frequent event in multiple myeloma. Br J Haematol (1999) 1.57
T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation (2001) 1.57
Two-dimensional x-ray waveguides and point sources. Science (2002) 1.56
Trimodal low-dose X-ray tomography. Proc Natl Acad Sci U S A (2012) 1.55
Prophage lambda induction of Escherichia coli K12 envA uvrB: a highly sensitive test for potential carcinogens. Proc Natl Acad Sci U S A (1976) 1.54
Autosomal dominant spondyloarthropathy. N Engl J Med (1989) 1.54
Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia (2012) 1.54
ABH and Lewis histo-blood group antigens in cancer. APMIS (2001) 1.54
Region-of-interest tomography for grating-based X-ray differential phase-contrast imaging. Phys Rev Lett (2008) 1.51
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Effects of a systematic approach to tobacco cessation in a community-based practice. Arch Fam Med (1997) 1.48
Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol (1993) 1.47
Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients. Bone Marrow Transplant (1995) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia (2011) 1.43
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol (1999) 1.42
The fractional Talbot effect in differential x-ray phase-contrast imaging for extended and polychromatic x-ray sources. J Microsc (2008) 1.41
Neutron phase imaging and tomography. Phys Rev Lett (2006) 1.41
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology (1998) 1.39
HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol (1999) 1.39
[Invasive aspergillosis in intensive care]. Ann Fr Anesth Reanim (1995) 1.39
Neutron dark-field tomography. Phys Rev Lett (2008) 1.38
Rehabilitation after severe head injury. Scand J Rehabil Med (1974) 1.38
Three-dimensional imaging of magnetic domains. Nat Commun (2010) 1.38
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood (1994) 1.37
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Neutron decoherence imaging for visualizing bulk magnetic domain structures. Phys Rev Lett (2008) 1.34
A micro tissue culture test for the titration and neutralization of rubella virus. Can J Microbiol (1969) 1.33
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum (1990) 1.32
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia (2009) 1.29
Simian virus 40 late promoter region able to initiate simian virus 40 early gene transcription in the absence of the simian virus 40 origin sequence. J Virol (1984) 1.29
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol (1983) 1.28
Design, fabrication, and characterization of diffraction gratings for neutron phase contrast imaging. Rev Sci Instrum (2008) 1.27
Highly absorbing gadolinium test device to characterize the performance of neutron imaging detector systems. Rev Sci Instrum (2007) 1.27
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am (1997) 1.26
Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis (2004) 1.25
Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med (1991) 1.25
High Sensitivity to Auxin is a Common Feature of Hairy Root. Plant Physiol (1990) 1.24
p53 and RAS gene mutations in multiple myeloma. Oncogene (1992) 1.24
Amphiphysin I antisense oligonucleotides inhibit neurite outgrowth in cultured hippocampal neurons. J Neurosci (1998) 1.23
B cell malignancies presenting with unusual bone involvement and mimicking multiple myeloma. Study of nine cases. Am J Med (1987) 1.23
Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. J Virol (1996) 1.23
An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. Proc Natl Acad Sci U S A (1994) 1.23
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients. Leukemia (2012) 1.23
14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. Cancer Res (1999) 1.23
Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med (1994) 1.22
The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia (1998) 1.22